Abpro Holdings, Inc. (ABPO)
OTCMKTS
· Delayed Price · Currency is USD
0.199
+0.038 (23.85%)
At close: Apr 28, 2026
Abpro Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
3
Market Cap
1.12M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evofem Biosciences | 20.18M |
| International Stem Cell | 9.10M |
| LakeShore Biopharma | 84.75M |
| Lyra Therapeutics | 398.00K |
| Eastgate Biotech | 137.64K |
| Iterum Therapeutics | 390.00K |
Abpro Holdings News
- 3 months ago - Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 - GlobeNewsWire
- 4 months ago - Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers - GlobeNewsWire
- 5 months ago - Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives - GlobeNewsWire
- 6 months ago - Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager - GlobeNewsWire
- 6 months ago - Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - GlobeNewsWire
- 1 year ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager - GlobeNewsWire
- 1 year ago - Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - GlobeNewsWire